Empowering Your Pipeline: Integrated Medicinal Chemistry Excellence
In drug discovery, the journey from a promising biological target to a clinical candidate is a high-stakes endeavor—one that demands precision, innovation, and a deep mastery of chemical complexity. At Oxeltis, we specialize in Medicinal Chemistry and Fine Organic Synthesis, providing the strategic expertise and technical excellence that tech transfer offices, biotechs, and mid-pharma innovators need to advance their programs with confidence.
Our approach seamlessly integrates science and strategy, ensuring your pipeline progresses efficiently through every critical milestone. From hit discovery to lead optimization, we deliver solutions that are data-driven, scalable, and aligned with your long-term goals.
01 — The first step
Hit Discovery: Precision at the Outset
The first step in drug discovery is not just about finding a hit — it's about finding the right hit. In this high-stakes phase, potential is either unlocked or lost. A poorly chosen starting point can derail even the most promising programs.
At Oxeltis, we understand that hit discovery demands a strategic blend of computational rigor and medicinal chemistry insight.
Our goal: to uncover hits that are active, scalable, synthetically accessible and aligned with your project's vision.
02 — The partnership
A Partnership for Smarter Discovery: Oxeltis & Molecular Forecaster
To redefine what’s possible in early-stage drug discovery, Oxeltis has joined forces with Molecular Forecaster, a pioneer in Computer-Aided Drug Design (CADD). Together, we don’t just identify hits—we engineer success from the very first step.
Our integrated approach addresses the most pressing challenges of hit discovery: speed, accuracy, and scalability.
01
Virtual screening at scale :
Unlocking chemical diversity
Molecular Forecaster’s state-of-the-art computational platform enables us to screen millions of compounds in silico, leveraging advanced algorithms to predict binding affinities, ADMET properties, and synthetic accessibility. By harnessing machine learning and structural bioinformatics, we rapidly narrow down vast chemical libraries to a highly curated set of candidates, each selected for its potential to become a viable hit.
02
Expert curation :
Bridging Theory and Practice
Not all computationally promising hits are created equal. Oxeltis' medicinal chemistry expertise ensures every candidate is validated, refined and prioritised:
- Synthetic feasibility:
Can the compound be efficiently synthesized at scale?
- Drug-likeness:
Does it meet the criteria for solubility, permeability, and metabolic stability?
- Developability:
Is it a strong foundation for future optimization?
This human-in-the-loop approach guarantees the hits we advance are both theoretically sound and practically viable.
03
Seamless Transition to Hit-to-Lead:
Building Momentum
Finding a hit is only the beginning. Oxeltis’ expertise in fine organic synthesis ensures that your selected hits are rapidly validated and optimized for the next phase. Our chemists work closely with your team to:
- Confirm activity through rigorous biochemical and cellular assays.
- Explore Structure-Activity Relationships (SAR) to identify the most promising chemical series.
- Lay the groundwork for lead optimization, so you can move forward with confidence.
By combining computational agility with hands-on chemical mastery, we don’t just deliver hits—we deliver a clear, actionable path forward.
Why This Partnership Works for You
In a landscape where time and precision are everything, our collaboration with Molecular Forecaster gives you a competitive edge. Whether you’re a biotech startup with limited resources or a mid-pharma company looking to de-risk your pipeline, we provide: